The team takes a look at the most recent legislation in Germany known as GSAV or the law for more safety in the supply of pharmaceuticals and its implications on the access to orphan drugs. GSAV was approved by the German cabinet on January 30, 2019 and is due to come into effect in August this year.
Presenter: Akshay Kumar
Contributor: Joanna Fernandes
Producer: Aparna Krishnan
Should the Middle East be a priority launch market for orphan drug manufacturers?
Rare Disease Day Special featuring Janet Bloor and Nick Meade - February 2022
P4A Insights: Trends to look out for in 2022
Special episode - Bluebird Bio: What went wrong? -December 2021:
Special episode featuring James Mackay - November 2021
Monthly Roundup - October 2021
Monthly RoundUp - September 2021
Monthly RoundUp: July 2021
Monthly RoundUp - June 2021
Monthly RoundUp - May 2021
Monthly RoundUp - April 2021
Monthly RoundUp - March 2021
Monthly RoundUp - February 2021
Rare Disease Day special episode: Reclaiming the rare disease patient’s voice
End of year 2020 review
Special episode: Gene Therapy access from a specialty pharmacy perspective
Weekly RoundUp: February 29, 2020
Weekly Roundup: December 30, 2019
Weekly Roundup: December 23, 2019
Weekly Roundup: November 12, 2019
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain